Skip to content
Benefits & EvidenceEvidence-Tiered

Acetyl Tetrapeptide-5 Benefits

What does Acetyl Tetrapeptide-5 actually do? We break down the evidence by tier — human data, animal studies, and in vitro research — with citations for every claim.

Quick Answer

Acetyl Tetrapeptide-5 primarily reduces under-eye puffiness, dark circles, and bags by decreasing vascular permeability and inhibiting glycation damage to capillaries. Clinical studies demonstrate up to 70% reduction in periorbital edema after 60 days. It strengthens microvascular integrity, preventing fluid accumulation and improving skin appearance.

→ Acetyl Tetrapeptide-5 Dosage→ Acetyl Tetrapeptide-5 Side Effects→ Full Acetyl Tetrapeptide-5 Profile

Evidence Tiers

HumanClinical or observational human dataAnimalPreclinical in vivo studiesIn VitroCell / tissue culture studies
Table of Contents

Mechanism of Action

Acetyl Tetrapeptide-5 reinforces endothelial tight junctions in periorbital capillaries, preventing fluid leakage. It also inhibits glycation of vascular and dermal proteins, protecting the delicate capillary network from damage. These actions improve microvascular integrity, reducing edema and the appearance of dark circles associated with vascular congestion.

Human Evidence

Human2 findings

Reduction in under-eye puffiness

Clinical studies demonstrate up to 70% reduction in periorbital edema after 60 days of twice-daily application.

PubMed 21456478 (2011) ↗

Improvement in dark circles

By strengthening capillaries and reducing fluid accumulation, Acetyl Tetrapeptide-5 can reduce dark circles caused by vascular congestion.

PubMed 27124923 (2016) ↗

In Vitro Research

In Vitro2 findings
In vitro (cell culture) findings are the earliest stage of evidence. They indicate mechanism plausibility but cannot confirm human effects.

Decreased vascular permeability

In vitro studies demonstrate that Acetyl Tetrapeptide-5 reinforces endothelial tight junctions, decreasing vascular permeability.

PubMed 21456478 (2011) ↗

Inhibition of glycation

In vitro, Acetyl Tetrapeptide-5 inhibits glycation of collagen and other dermal proteins.

PubMed 33504021 (2021) ↗

What's Proven vs What's Still Unknown

✓ What the Evidence Supports

  • ✓Reduces under-eye puffiness (clinical studies)
  • ✓Decreases vascular permeability (in vitro)
  • ✓Inhibits glycation of dermal proteins (in vitro)
  • ✓Improves microvascular integrity

? Still Unknown or Unconfirmed

  • ?Long-term efficacy beyond 60 days
  • ?Effectiveness on dark circles caused by hyperpigmentation
  • ?Synergistic effects with other cosmetic ingredients

Frequently Asked Questions

What is the main benefit of Acetyl Tetrapeptide-5?
The primary benefit is the reduction of under-eye puffiness and bags by decreasing fluid accumulation in the periorbital area. It also improves the appearance of dark circles related to vascular congestion.
Is Acetyl Tetrapeptide-5 effective for all types of dark circles?
Acetyl Tetrapeptide-5 is most effective for dark circles caused by vascular issues. It may not be as effective for dark circles caused by hyperpigmentation or thin skin.
Can Acetyl Tetrapeptide-5 prevent under-eye puffiness from recurring?
Consistent use of Acetyl Tetrapeptide-5 can help prevent under-eye puffiness by maintaining capillary integrity and reducing fluid accumulation. However, lifestyle factors can still influence the degree of puffiness.
How does Acetyl Tetrapeptide-5 differ from other peptides for under-eye care?
Acetyl Tetrapeptide-5 is specifically designed to target vascular permeability and fluid accumulation. Other peptides may focus on collagen production or skin firmness. Combining different peptides can provide comprehensive under-eye care.

References

  1. 1
    Eyeseryl (Acetyl Tetrapeptide-5): evaluation of an anti-edema peptide for periorbital application(2011)PubMed ↗
  2. 2
    Peptide-based approaches to periorbital aging: targeting puffiness, dark circles, and fine lines(2016)PubMed ↗
  3. 3
    Cosmeceutical peptides in the framework of sustainable wellness economy(2021)PubMed ↗

Last updated: 2026-02-19